Posts

Posted on

NYSE Content Update: Reformation Scores Winning Session in NYSE Debut

PR Newswire

NYSE issues a pre-market daily advisory direct from the trading floor.

NEW YORK, July 31, 2026 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Kristen Scholer delivers the pre-market update on July 31st

  • Shares of sustainable womenswear Reformation (NYSE: REF) closed fractionally higher on Thursday following its IPO on the NYSE.
    • CEO Hali Borenstein will join NYSE Live to discuss the strategy of going public and what the firm has planned in 2026.
  • Global X NYSE 100 ETF component Amazon is eyeing double-digit gains at the open following its Q2 earnings report.
    • Announced quarterly revenue of $200.6 billion.
    • AWS sales expanded by 37% year-over-year.
    • CEO Andy Jassy says the company expects CapEx spending to reach $220 billion this year due to higher memory costs.


Opening Bell

Reformation (NYSE: REF) celebrates its IPO on the NYSE.


Closing Bell


IronHorse Capital celebrates the Conductor Global Value ETF

For market insights, IPO activity, and today’s opening bell, download the NYSE TV App:

TV.NYSE.com

Jersey Mike's at the NYSE on July 30

NYSE Logo

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-content-update-reformation-scores-winning-session-in-nyse-debut-302840026.html

SOURCE New York Stock Exchange

Posted on

Smurfit Westrock plc: Form 10-Q for the Quarterly Period Ended June 30, 2026

Smurfit Westrock plc: Form 10-Q for the Quarterly Period Ended June 30, 2026

DUBLIN–(BUSINESS WIRE)–
Today Smurfit Westrock plc (the “Company”) filed its quarterly report on Form 10-Q for the quarterly period ended June 30, 2026 with the U.S Securities and Exchange Commission (the “SEC”). The Form 10-Q is available to view on the SEC’s website at: https://www.sec.gov and the Company’s website at: https://investors.smurfitwestrock.com/financials/sec-filings/default.aspx

Niall Keane

Company Secretary

+353 (0)1 202 7000

KEYWORDS: North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Finance Manufacturing Professional Services Packaging Chemicals/Plastics

MEDIA:

Posted on

IonQ Completes Acquisition of SkyWater Technology

IonQ Completes Acquisition of SkyWater Technology

Creates the Only Vertically Integrated Full-Stack Quantum Platform Company

Accelerates IonQ’s Fault-Tolerant Quantum Computing Roadmap

Facilitates Secure End-to-End Design through Delivery of IonQ’s Platform of Next-Generation Quantum Computing, Quantum Networking, Quantum Security, and Quantum Sensing Technologies

SkyWater Will Continue to Serve Customers as a U.S.-based Semiconductor Foundry

COLLEGE PARK, Md. & BLOOMINGTON, Minn.–(BUSINESS WIRE)–
IonQ (NYSE: IONQ), the world’s leading quantum platform company, today completed its acquisition of SkyWater Technology (NASDAQ: SKYT), the largest exclusively U.S.-based semiconductor foundry.

“Acquiring SkyWater crystalizes IonQ’s vision to serve as a technology leader, merchant supplier and ecosystem enabler across the entire quantum industry. We are investing in capabilities from quantum foundry and advanced packaging to manufacturing and commercialization that the quantum ecosystem requires for future growth,” said Niccolo de Masi, Chairman and Chief Executive Officer of IonQ. “Building upon our existing merchant supplier track record providing quantum solutions for our customers, we expect this acquisition to accelerate all quantum platforms across the industry.”

“This combination enables IonQ to drive our quantum computing roadmap and secure a fully scalable supply chain domestically. It unlocks IonQ‘s semiconductor-based approach to manufacturing new generations of our quantum computers, while ensuring SkyWater’s ability to deliver the excellent quality and attention customers expect,” said de Masi, who added, “Secure chip design, fabrication, and packaging will deliver vertical integration across our full stack of quantum applications for land, sea, air, and space.”

“Joining the IonQ team marks a pivotal moment in SkyWater’s evolution,” said Thomas Sonderman, Chief Executive Officer of SkyWater Technology. “As the largest semiconductor foundry based in the U.S., SkyWater is already the partner of choice for advanced development and manufacturing services in both the public and private sectors as quantum computing shifts from research to manufacturing. Being part of IonQ will accelerate multiple engineering pathways for next-generation quantum chips, delivering speed, precision, and scale. Importantly, SkyWater remains fully committed to all of our semiconductor foundry customers and will continue as the quantum supplier of choice with an even broader set of quantum sensing and quantum networking solutions for our customers and partners.”

Following today’s closing, SkyWater will operate as a subsidiary under the SkyWater name. Sonderman will lead the subsidiary and report to de Masi, which will ensure the continued delivery of industry-leading Advanced Technology, Wafer, and Advanced Packaging Services as well as atomic clocks and quantum interconnects to all SkyWater customers.

Transaction Details

Under the terms of the agreement, SkyWater shareholders are receiving $15.00 in cash and 0.4883 shares of IonQ common stock for each share of SkyWater common stock held at close of the transaction. The closing followed receipt of required regulatory approvals. The combined company is expected to hold its second quarter earnings call on Wednesday, Aug. 5, 2026 after the U.S. market closes and an investor day in the third quarter of 2026 (Sept. 8).

About IonQ

IonQ, Inc. [NYSE: IONQ] is the world’s leading quantum platform and foundry – delivering integrated quantum solutions across computing, networking, sensing, and security. IonQ’s newest generation of quantum computers, the IonQ Tempo, is the latest in a line of cutting-edge systems. Earlier systems have helped customers and partners including Amazon Web Services, AstraZeneca, and NVIDIA achieve a 20x performance increase over previous quantum solutions and accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. In 2025, the company achieved 99.99% two-qubit gate fidelity, setting a world record in quantum computing performance.

Headquartered in College Park, Maryland, IonQ has operations in California, Colorado, Massachusetts, Tennessee, Washington, Italy, South Korea, Sweden, Switzerland, Canada, and the United Kingdom. Our quantum computing services are available through all major cloud providers, while we also meet the needs of networking and sensing customers across land, sea, air, and space. IonQ is making quantum platforms more accessible and impactful than ever before. Learn more at IonQ.com.

About SkyWater

SkyWater Technology is securing America’s silicon foundation as the largest U.S.-based semiconductor foundry. A trusted partner to both commercial customers and federal defense programs, SkyWater’s Technology as a Service model empowers innovators to bring emerging technologies like quantum computing and next-generation systems from concept to reality. With state-of-the-art facilities in Minnesota, Florida, and Texas, SkyWater specializes in foundational nodes and advanced packaging to support the nation’s critical infrastructure, strengthen supply chain resilience, and ensure long-term U.S. technology leadership. SkyWater is a DMEA-accredited Category 1A Trusted Foundry. To learn more, visit SkywaterTechnology.com.

Note to Investors Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding IonQ’s quantum computing roadmap, the benefits to IonQ of vertical integration and SkyWater’s future operations. In some cases, you can identify these statements by forward-looking words such as “pending,” “look forward,” “accelerate,” “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” “confident,” “position,” “become,” “on track,” “ensure,” “ongoing” and other similar expressions. These statements are only predictions based on our expectations and projections about future events as of the date of this press release and are subject to a number of risks, uncertainties and assumptions that may prove incorrect, any of which could cause actual results to differ materially from those expressed or implied by such statements, including, among others, those described under the heading “Risk Factors” in our most recently filed Annual Reports on Form 10-K filed with the Securities and Exchange Commission. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement we make. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as otherwise required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

IonQ Media Contact:

Cheryl Krauss

[email protected]

IonQ Investor Contact:

[email protected]

SkyWater Media Contact:

Tammy Swanson

[email protected]

KEYWORDS: Minnesota Maryland United States North America

INDUSTRY KEYWORDS: Automotive Technology Research Other Defense Contracts Automotive Manufacturing Logistics/Supply Chain Management Manufacturing Defense Utilities Semiconductor Other Automotive Alternative Energy Energy Transport Software Networks Internet Science Hardware

MEDIA:

Posted on

Steakholder Foods Ltd. Announces Up To $10.5 Million Private Placement


$3.5 million upfront with up to approximately $7 million of potential additional gross proceeds upon the exercise in full of warrants

Rehovot, Israel, July 31, 2026 (GLOBE NEWSWIRE) — Steakholder Foods Ltd. (Nasdaq: STKH) (“Steakholder Foods” or the “Company”), a global leader in 3D-printing technology for production of whole cuts of plant-based meat, today announced the entry into the definitive agreements for purchase and sale of an aggregate of 1,750,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each ADS representing twelve thousand (12,000) ordinary shares of the Company, short-term Series E warrants to purchase up to an aggregate of 1,750,000 ADSs and Series F warrants to purchase up to an aggregate of 1,750,000 ADSs, at a combined purchase price of $2.00 per ADS (or ADS equivalent in lieu thereof) and accompanying series warrants in a private placement. The short-term Series E warrants and the Series F warrants will have an exercise price of $2.00 per ADS and will be exercisable on or after the date of the approval by the shareholders of the Company of the increase in authorized ordinary shares of the Company (the “Authorized Share Increase Date”). The short-term Series E warrants will expire 18 months following the later of the Authorized Share Increase Date and the Effectiveness Date (as defined below) and the Series F warrants will expire five years following the later of the Authorized Share Increase Date and the Effectiveness Date. The private placement is expected to close on August 3, 2026, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction.

The aggregate gross proceeds to the Company from this offering are expected to be approximately $3.5 million before deducting the placement agent’s fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the exercise of the short-term Series E warrants and the Series F warrants, if fully exercised on a cash basis, will be approximately $7 million. No assurance can be given that any of the series warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the series warrants.  The Company intends to use the net proceeds from this offering for funding research and development and the growth of its business as well as for other working capital and general corporate purposes.
  
The securities described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and/or Regulation D promulgated thereunder and, along with the ordinary shares of the Company represented by ADSs underlying the warrants, have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the private placement and ordinary shares of the Company represented by ADSs underlying the warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the investors, the Company has agreed to file a resale registration statement covering the securities described above (such date of effectiveness of the resale registration statement, the “Effectiveness Date”).
  
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Steakholder Foods

Steakholder Foods is at the forefront of transforming the alternative protein industries through its advanced technology. Founded in 2019, Steakholder Foods is utilizing advanced technologies to revolutionize the food industry, and is preparing to launch PerfectaTM Premium Plant-Based Meat in the U.S. market in 2026, under the slogan “Plant-Based Meat, Perfected!” Perfecta is positioned as a next-generation, plant-based protein platform, whose launch is planned to begin with a phased rollout in the Northeastern United States, followed by retail expansion as the supply chain and distribution scale.

Steakholder Foods also specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These innovative tools are designed to help manufacturers of all sizes efficiently produce foods that meet and exceed consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production.

Steakholder Foods’ expertise in creating alternative proteins products that replicate the complex textures of traditional meats such as beef steaks, white fish, shrimp, and eel. The company is also exploring the integration of cultivated cells, preparing for future advancements in food technology.

For more information, please visit: https://steakholderfoods.com

Forward-Looking Statements

This press release contains forward-looking statements concerning Steakholder Foods’ business, operations and financial performance and condition as well as plans, objectives, and expectations for Steakholder Foods’ business operations and financial performance and condition. Any statements that are not historical facts may be deemed to be forward-looking statements. Forward-looking statements reflect Steakholder Foods’ current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause Steakholder Foods’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and are typically identified with words such as “may,” “could,” “should,” “will,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “aim,” “intend,” “plan” or words or phases of similar meaning and include, without limitation, the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, the receipt of shareholder approval of the Authorized Share Increase, and the potential exercise of the series warrants prior to their expiration and potential proceeds therefrom. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, Steakholder Foods’ expectations regarding the success of the technologies which it is developing, which may require significant additional work before Steakholder Foods can potentially launch commercial sales; Steakholder Foods’ research and development activities associated with printing technologies, including three-dimensional food printing, which involves a lengthy and complex process; Steakholder Foods’ ability to obtain and enforce its intellectual property rights and to operate its business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties; and other risks and uncertainties, including market and other conditions and those identified in Steakholder Foods’ Annual Report on Form 20-F for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on April 30, 2026.  New risks and uncertainties may emerge from time to time, and it is not possible for Steakholder Foods to predict their occurrence or how they will affect Steakholder Foods. If one or more of the factors affecting Steakholder Foods’ forward-looking information and statements proves incorrect, then Steakholder Foods’ actual results, performance or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, Steakholder Foods cautions you not to place undue reliance on its forward-looking information and statements. Steakholder Foods disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law.

Press Contact:

Steakholder Foods Ltd.‍
[email protected]


Investor Contact:

Steakholder Foods Ltd.
[email protected]



Posted on

MCN Adjourns Special Meeting of Shareholders Until August 26, 2026

CHICAGO, July 31, 2026 (GLOBE NEWSWIRE) — XA Investments, LLC, manager of XAI Madison Equity Premium Income Fund (MCN) (the “Fund”) announced it has adjourned the Fund’s Special Meeting of Shareholders (the “Meeting”) due to a lack of quorum. Shareholders are urged to please submit their votes on the proposal to approve a new sub-advisory agreement for the Fund as soon as possible. The Meeting will reconvene on Thursday, August 26, 2026, at 8:45 a.m. Central Time, at the offices of XA Investments, LLC at 321 N Clark St #2430, Chicago, Illinois.

Shareholders of record of the Fund as of the close of business on June 2, 2026, are entitled to vote at the Meeting. Whether or not shareholders plan to attend the Meeting, it is important that their shares be represented and voted at the Meeting.


How to Vote

Use one of the following options to vote:

  • By Internet: Visit the website listed on your proxy card, enter your control number and follow the simple on-screen instructions.
  • By Phone: Call the toll-free number listed on your proxy card.
  • By Mail: Sign and return the proxy card in the enclosed postage-paid envelope.

If shareholders do not have their proxy card and need assistance voting their shares or if they have any questions, please contact the Fund’s proxy solicitation firm, Okapi Partners LLC, toll-free at (855) 305-0855 or by email at

[email protected]

.

The Board of Trustees of the Fund believes the sub-advisory agreement is in the best interests of the Fund and recommends that shareholders vote “FOR” the proposal.

The proxy statement contains important information regarding the vote and shareholders of the Fund are urged to read the proxy statement and accompanying materials carefully. The proxy statement is also available at https://www.okapivote.com/MCN/.

About XA Investments

XA Investments LLC is a Chicago-based firm founded by XMS Capital Partners in 2016. XAI serves as the investment adviser for two listed closed-end funds and an interval closed-end fund. In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XAI offers custom product build and consulting services, including product development and market research, marketing and fund management. XAI believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. For more information, please visit www.xainvestments.com.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

NOT FDIC INSURED NO BANK GUARANTEE MAY LOSE VALUE
     

Media Contact: 

Kimberly Flynn, President
XA Investments LLC
Phone: 888-903-3358
Email: [email protected]
www.xainvestments.com



Posted on

DPC Holdings Receives Upgrade From Moody’s to Ba2 Outlook Upgraded to Positive

DPC Holdings Receives Upgrade From Moody’s to Ba2 Outlook Upgraded to Positive

ST HELIER, Jersey–(BUSINESS WIRE)–
DPC Holdings (NYSE: DPC) (“Doncasters”) reported on July 30, 2026, that Moody’s upgraded the corporate family rating (CFR) of Alloy Parent Limited (Doncasters) three notches to Ba2 from B2 and changed the outlook to positive from stable.

Moody’s reported that the Ba2 rating reflects Doncasters’ strong balance sheet following the successful Initial Public Offer, the diversified revenue streams across end-markets and platforms and between original equipment and aftermarket activities, and the top three positions on critical long-term programs. Moody’s further notes that the strong balance sheet provides material capacity to fund organic investment and pursue mid-sized inorganic growth opportunities.

Doncasters’ Chief Financial Officer stated “We are pleased that Moody’s has recognized the significant progress Doncasters has made in strengthening its balance sheet and enhancing our financial flexibility to materially reduce our financial leverage. We remain committed to maintaining a disciplined approach to capital allocation and delivering sustainable long-term value for all stakeholders.”

About Doncasters

Doncasters is a leading independent manufacturer of complex, highly engineered precision cast components and nickel‑ and cobalt-based superalloys primarily serving the high growth Aerospace and IGT end markets. We primarily manufacture products that operate across some of the most in-demand aeroengine and gas turbine platforms, and through decades of operations, we have developed deep engineering expertise, technical know-how, and a collaborative, customer-centric culture that provides solutions to our OEM customers’ most complex casting challenges. Doncasters operates 14 advanced manufacturing facilities across North America, Europe, the United Kingdom and Asia, serving a broad blue-chip client base worldwide and maintaining a leading position in specialist manufacturing and casting of superalloys.

Lucy Sharma

DPC Holdings Investor Relations

[email protected]

KEYWORDS: Jersey Europe

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Professional Services Engineering Aerospace Manufacturing Finance Other Manufacturing

MEDIA:

Logo
Logo
Posted on

Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering

MINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Nuwellis also received approximately $3.1 Million in gross proceeds from the exercise of previously issued warrants which were issued in connection with the Company’s June 2026 public offering.

In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,310,890 shares of common stock. The warrants have an exercise price of $2.59 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of effectiveness of the registration statement for the purposes of registering the shares of common stock underlying the warrants.

The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 3, 2026, subject to the satisfaction of customary closing conditions.

Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offerings.

The securities described above (excluding the warrants and the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-280647), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on July 9, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at [email protected].

The warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, statements with respect to the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds from the offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offerings, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Relations:

CORE IR
[email protected]

Media Contact:

CORE PR
[email protected]



Posted on

Global Water Resources Declares Monthly Dividend

PHOENIX, July 31, 2026 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, has declared under its dividend policy a monthly cash dividend in the amount of $0.02533 per common share (an annual dividend rate of $0.30396 per share).

The dividend will be payable on August 31, 2026, to holders of record at the close of business on August 17, 2026.

About Global Water Resources

Global Water Resources, Inc. is a leading water resource management company that owns and operates 39 systems which provide water, wastewater, and recycled water service. The company’s service areas are located primarily in growth corridors around metropolitan Phoenix and Tucson. Global Water recycles over 1 billion gallons of water annually with 19.8 billion gallons recycled since 2004.

The company has been recognized for its highly effective implementation of Total Water Management (TWM). TWM is an integrated approach to managing the entire water cycle that involves owning and operating water, wastewater and recycled water utilities within the same geographic area in order to maximize the beneficial use of recycled water. It enables smart water management programs such as remote metering infrastructure and other advanced technologies, rate designs, and incentives that result in real conservation. TWM helps protect water supplies in water-scarce areas experiencing population growth.

Global Water has received numerous industry awards, including national recognition as a ‘Utility of the Future Today’ for its superior water reuse practices by a national consortium of water and conservation organizations led by the Water Environment Federation (WEF). The company also received Cityworks’ Excellence in Departmental Practice Award for demonstrating leadership and creativity in applying public asset management strategies to daily operations and long-term planning.

To learn more, visit www.gwresources.com.

Company Contact:

Michael Liebman
CFO and SVP
Tel (480) 999-5104
Email Contact

Investor Relations Contact:

Ron Both or Grant Stude
Encore Investor Relations
Tel (949) 432-7450
Email Contact



Posted on

Brera Holdings (NASDAQ: SLMT) (“Solmate Infrastructure”) Partners with Anagram as a Strategic Ecosystem Partner Ahead of an Expected Major Expansion of its Institutional Platform

Brera Holdings (NASDAQ: SLMT) (“Solmate Infrastructure”) Partners with Anagram as a Strategic Ecosystem Partner Ahead of an Expected Major Expansion of its Institutional Platform

DUBLIN–(BUSINESS WIRE)–
Solmate Infrastructure PLC (NASDAQ: SLMT) (“Solmate” or the “Company”), a next-generation digital infrastructure company focused on blockchain, staking, and AI infrastructure, today announced that it has selected Anagram as a strategic ecosystem partner, marking the next phase of the Company’s strategy to build a leading institutional blockchain infrastructure platform.

The partnership is expected to support Solmate’s continued expansion across the Solana ecosystem, providing the Company with access to Anagram’s network, market expertise, and deep relationships across blockchain infrastructure, staking, and institutional digital assets.

Anagram forms part of a broader partnership strategy through which Solmate is assembling a group of leading infrastructure and staking organizations to support the development, operation, and commercial expansion of its platform.

These prospective partnerships are intended to materially expand the scale, capabilities, and economic potential of the Company’s staking infrastructure, while strengthening Solmate’s position within the institutional Solana ecosystem.

“Anagram’s network, market expertise, and deep understanding of the Solana landscape is designed to help Solmate identify opportunities, build the right institutional relationships, and accelerate the commercial development of our infrastructure platform,” said Ron Sade, Chief Executive Officer of Solmate Infrastructure.“This partnership strengthens the foundation we are building around Solana and comes as we prepare to add further staking partners that aims to significantly expand the scale and capabilities of the platform.”

“Reliable validator infrastructure is built through long-term operational excellence,” said Joe Eagan, Co-Founder of Anagram. “Anagram is excited to partner with Solmate to support its validator strategy and help strengthen the foundation of the Solana network as institutional participation continues to grow.”

The Anagram partnership builds on Solmate’s recently announced collaboration with Kraken Institutional, which supports the Company’s Solana validator infrastructure through a structure combining qualified custody with staking capabilities. Together, these relationships reflect Solmate’s broader strategy of assembling institutional-grade partners to strengthen its platform, improve staking economics, and support long-term recurring revenue growth.

About Solmate Infrastructure PLC

Solmate Infrastructure PLC (NASDAQ: SLMT) is building next-generation digital infrastructure spanning blockchain, staking, AI infrastructure, and high-performance computing. The Company is focused on creating long-term shareholder value through the ownership, operation, and optimization of mission-critical digital infrastructure assets.

About Anagram

Anagram Ltd. is a holding company building novel products and infrastructure across frontier technology. Anagram Staking Services is a subsidiary of Anagram Ltd. focused on performant validator infrastructure for blockchain protocols, primarily in the Solana ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “aim,” “believe,” “continue,” “could,” “estimate,” “expect,” “designed,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions. These statements include, but are not limited to, statements regarding the Company’s business strategy, future growth, the expected benefits of the Company’s partnership with Anagram, prospective partnerships, the future development, expansion, scale, capabilities and economic potential of the Company’s institutional blockchain and staking infrastructure platform, the development of institutional relationships, staking economics, recurring revenue growth, market opportunities and shareholder value creation. These forward-looking statements are based on current expectations, estimates, assumptions and projections and involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Additional information concerning these and other risks is contained in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.

Media Contact:

Wachsman

[email protected]

KEYWORDS: North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Professional Services Technology Blockchain Cryptocurrency Finance Software

MEDIA:

Logo
Logo
Posted on

Cerenome Launches as an Integrated CNS Oncology Company

Formerly known as Plus Therapeutics, Cerenome integrates precision diagnostics, targeted therapeutics, and artificial intelligence to improve how CNS cancers are detected, treated, and understood

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company’s name will become Cerenome, Inc. The Company’s common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “CNSY,” effective market open on the same day.

The new name reflects the Company’s de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. The Company has expanded beyond targeted radiotherapeutics because effective solutions for CNS cancer will require a multimodal approach. Cerenome will integrate precision diagnostics, targeted therapeutics, and proprietary data within a single organization to improve how CNS cancers are detected, treated, and understood.

“Fifty years of medical research has taught us that CNS cancers are not an isolated set of localized cancers but a systems problem requiring a comprehensive and unified approach to solving them,” said Marc H. Hedrick, M.D., Cerenome President and Chief Executive Officer. “This journey began in earnest a couple of years ago with the acquisition of our diagnostic platform and our more recent native artificial intelligence partnership. We are already seeing the fruits of the integration of diagnostics, therapeutics, and advanced data analytics. We are excited about our future and look forward to explaining the opportunity in greater detail to stockholders and ultimately delivering improved outcomes for patients.”

Cerenome’s strategy is built on three integrated and mutually reinforcing platforms:

  • The Company’s CNSide® Diagnostic is a commercially available and reimbursed cerebrospinal fluid (CSF)-based platform supporting the cellular and multiomic characterization of cerebrospinal fluid for the diagnosis and management of patients with or at risk for CNS cancers
  • REYOBIQ™ (rhenium Re186 obisbemeda) is Cerenome’s lead investigational targeted radiotherapeutic being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancer, designed to deliver targeted radiation directly to CNS tumors while limiting systemic exposure
  • The Company’s data analytics and artificial intelligence platform is a proprietary and multifaceted initiative designed to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making

For patients, this integrated approach has the potential to enable earlier detection, more informed treatment decisions, disease monitoring and ultimately better outcomes. For healthcare providers, Cerenome can offer a more comprehensive systems view of the disease from diagnostic interrogation to longitudinal patient management. For academic and biopharmaceutical partners, the platform creates opportunities for research, clinical development, and collaboration. For investors, the integration of commercial diagnostics, clinical-stage therapeutics, and proprietary longitudinal data establishes a highly differentiated business case anchored by its lead assets CNSide, Reyobiq and recent artificial partnership with Ephemeral Technologies.

“The new name Cerenome combines ‘Cere,’ representing the brain and central nervous system, with ‘nome,’ reflecting the expansive knowledge sets that power precision oncology,” Dr. Hedrick added. “However, our mission of improving survival in CNS cancers has not changed. We remain committed to commercializing innovative products for patients with CNS cancers while building a platform designed for long term value creation.”

The Company’s existing CNSide® and REYOBIQ™ brands will remain unchanged.

Nasdaq Trading Information

The Company’s common stock will continue to be listed on the Nasdaq Capital Market and will trade under the ticker symbol “CNSY” beginning August 3, 2026. The corporate name and ticker symbol changes do not affect shareholders’ ownership interests. Existing shares held in brokerage or book-entry accounts will automatically reflect the new corporate name and ticker symbol, and shareholders are not required to take any action.

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value.

Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding the effectiveness of the Company’s expected name change and ticker symbol change, the anticipated date of trading of the Company’s common stock on the Nasdaq Capital Market under its new ticker symbol, clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the receipt of necessary regulatory approvals.

Investor Contact

CORE IR
[email protected]